Mankind Pharma Receives ‘C-’ ESG Rating

New Delhi | June 5, 2025 – Mankind Pharma Limited (NSE: MANKIND | BSE: 543904) has been assigned an overall ESG (Environmental, Social, and Governance) score of 38.98 with a rating of ‘C-’ by ISS ESG, as per the latest disclosure to stock exchanges dated June 4, 2025. The rating was based solely on publicly available information, and the company clarified that it has not verified any of the data used in the rating process.

The ESG Risk Rating assesses a company’s exposure to environmental, social, and governance risks and its effectiveness in managing them. It guides investors in identifying companies with sustainable and responsible business practices.

Voluntary Disclosure Under SEBI Regulations

ISS ESG made the disclosure in compliance with Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated November 11, 2024, based on publicly available data for Mankind Pharma.

How Did Investors Take The News?

In the opening market session, the shares of Mankind Pharma were trading at ₹2,370, up 1.03% and ₹24.10. This shows that the investors did not take the news negatively, as it was not a voluntary submission by the company, and the ratings were provided based only on publicly available information.

What’s Ahead? 

While the current ESG score stands at 38.98 (C-), stakeholders and investors expect Mankind Pharma to provide further disclosures or improvements in ESG practices if the company takes steps to formally verify and enhance the underlying metrics evaluated by ESG rating agencies.

The company’s decision to disclose this rating, despite its preliminary and unverified nature, demonstrates that the company is transparent and seeks to further improve its ratings.

About the Company

Mankind Pharma Limited, headquartered in New Delhi, is a leading Indian pharmaceutical company known for its presence across prescription medicines, consumer healthcare, and veterinary products. The company has been focusing on affordability, innovation, and rural outreach to expand its healthcare impact across India and emerging markets.

REF: https://nsearchives.nseindia.com/corporate/MANKIND2_04062025233012_ESG_Rating_sd.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations